Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.

BMC infectious diseases - 21 Sept 2021

Wang Ying-Wen, Lee Wei-Ping, Huang Yi-Hsiang, Hou Ming-Chih, Lan Keng-Hsin

Abstract excerpt

BACKGROUND: Previous studies reported worsened lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antivirals (DAAs) treatment. This study aimed to investigate the effect of sofosbuvir (SOF)-based DAAs on changes in low-density lipoprotein (LDL) in HCV patients. METHODS: A systematic review of articles published before 31 May 2021 was conducted by searching MEDLINE, Cochrane...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Lipoproteins, LDL

Share to Ribavirin

Share to Sofosbuvir

Share to Sustained Virologic Response

Source

Open in PubMed Open full text

Identifiers

PMID: 34548026
DOI: 10.1186/s12879-021-06657-9
PMCID: PMC8454153

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.PMID 34548026Read ↗

Metabolic changes in chronic hepatitis C patients receiving direct acting antiviralsSemantic proximity Read ↗

Effect of antiviral therapy for HCV on lipid levels.Semantic proximity Read ↗

Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol.Semantic proximity Read ↗

Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.Semantic proximity Read ↗

Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.Semantic proximity Read ↗

Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis.Semantic proximity Read ↗

Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.Semantic proximity Read ↗

The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis.Semantic proximity Read ↗

Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment.Semantic proximity Read ↗

Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.Semantic proximity Read ↗

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.